Answers are grounded in this paper and cite their sources.
Parkinson’s disease (PD) progression is heterogeneous, which makes individual prognosis difficult. We developed a multimodel framework to carry out approximately one-year forecasting of MDS-UPDRS Parts I–III in participants from the Parkinson’s Progression Markers Initiative (PPMI; 49% enrolled with PD), using patient-disjoint evaluation with leakage controls. The calibration-selected deployable strategy achieved MAEs of 1.188 (95% CI 1.113–1.269), 2.223 (2.070–2.379), and 5.110 (4.759–5.478) for Parts I–III (R2 of 0.541, 0.825, and 0.802). Retrospective Oracle selection among four candidate models lowered the MAE by about 31–35% relative to the best single candidate chosen on calibration data. However, the deployable strategy recovered only 4.4% (95% CI −1.2 to 8.9), 7.9% (3.4 to 11.6), and 5.2% (0.4 to 9.3) of this headroom, indicating large model complementarity but limited predictability in terms of which model is best for a given patient. In a complementary Hoehn–Yahr (HY) analysis, 83.11% of 9–15-month transitions kept the same stage. Among HY-stable transitions, 70.17% showed some degree of worsening in at least one MDS-UPDRS domain, but only 33.41% exceeded the published minimal clinically important difference. A calibrated model for one-year HY progression achieved ROC-AUC of 0.700±0.016 and PR-AUC of 0.235±0.017 at 11.23% prevalence, with a Brier score of 0.094±0.004. These findings separate retrospective complementarity from prospective recoverability.
No takes yet. Share an insight, caveat, or question.
Mushta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: